VYNE THERAPEUTICS INC (VYNE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.50+8.46%
Close 2026-08-24 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VYNE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress clinical trials of YB-101, a first-in-class anti-TSHR antibody, including Phase 2a/2b trials and data readouts in Graves' Disease and thyroid eye disease.
Stated as a priority in 2 distinct disclosures including 2026-Q1 and 2026-07-28. Management initiated dosing in the Phase 2a/2b trial for Graves' Disease and expects Phase 2a data in the second half of 2027, with Phase 2b planned for 1H 2028. Ongoing Phase 1 trials in China for TED and GD support clinical progress. The trajectory shows active advancement consistent with management's stated development plans.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Yarrow advancing YB-101 to redefine treatment of Graves' Disease and TED; Phase 2a/2b trial expected to start Q2 2026.”
Manage cash and cost structure to ensure sufficient funding for operations into the first half of 2027.
Stated in 3 disclosures including 2025-Q2, 2025-Q3, and 2026-Q2. Management projected cash runway into first half of 2027 based on $39.6 million cash and investments as of mid-2025, supported by cost reductions. Post-merger financings totaling approximately $200 million extend runway into 2028. The trajectory shows successful extension of cash runway beyond initial targets.
“Cash balance expected to support operations into 2028 following merger and financings.”
“Cash, cash equivalents and investments of approximately $39.6 million as of June 30, 2025.”
“Cost reductions expected to extend cash runway into first half of 2027.”
Finalize the reverse merger with Yarrow Bioscience, including reverse stock split, rebranding, and Nasdaq listing under new ticker.
Stated in 2 disclosures around July 2026. Management completed the merger with Yarrow Bioscience, executed a 1-for-50 reverse stock split, and rebranded with Nasdaq ticker 'YARW'. Post-merger shares outstanding are approximately 2.8 million. The merger and rebranding were completed as planned, delivering on this priority.
Control operating expenses to reduce net losses and improve financial sustainability.
Stated in 3 quarters including 2025-Q2, 2026-Q1, and 2026-Q2. Operating losses improved from $7.5 million in 2025-Q2 to $3.1 million in 2026-Q2, while revenue increased from $69,000 to $97,000 over the same period. Management's focus on cost reductions aligns with this improving financial trend, indicating progress in managing expenses and reducing losses.
“Operating loss of $3.1 million with revenue of $97,000.”
“Operating loss of $3.8 million with revenue of $86,000.”
“Operating loss of $7.5 million with revenue of $69,000.”
Focus on growing revenue by advancing product commercialization and market adoption.
Over the trailing year it converted 1.16x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
14 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.